Pulse Pharmaceuticals received approval from the Drugs Controller General of India on August 20, 2026, for its nano-carrier entrapped Vitamin D3 oral dispersion.
Managing Director K. V. Rambabu stated the approval is a global first and will help the firm seek regulatory nods in the US and South Asian markets.
The Hyderabad-based company, which has worked on nanotechnology since 2010, holds five patents across India, the US, Russia, Mexico, and Australia.